GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NLS Pharmaceutics Ltd (NAS:NLSP) » Definitions » DeferredTaxAndRevenue

NLS Pharmaceutics (NLS Pharmaceutics) DeferredTaxAndRevenue : $0.00 Mil (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is NLS Pharmaceutics DeferredTaxAndRevenue?

Deferred Tax And Revenue represents the current portion of obligations, which is a liability that usually would have been paid but is now pas due.

NLS Pharmaceutics's current deferred tax and revenue for the quarter that ended in Dec. 2023 was $0.00 Mil.

NLS Pharmaceutics DeferredTaxAndRevenue Historical Data

The historical data trend for NLS Pharmaceutics's DeferredTaxAndRevenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NLS Pharmaceutics DeferredTaxAndRevenue Chart

NLS Pharmaceutics Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
DeferredTaxAndRevenue
Get a 7-Day Free Trial - - - - -

NLS Pharmaceutics Semi-Annual Data
Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
DeferredTaxAndRevenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

NLS Pharmaceutics DeferredTaxAndRevenue Related Terms

Thank you for viewing the detailed overview of NLS Pharmaceutics's DeferredTaxAndRevenue provided by GuruFocus.com. Please click on the following links to see related term pages.


NLS Pharmaceutics (NLS Pharmaceutics) Business Description

Traded in Other Exchanges
N/A
Address
The Circle 6, Zurich, CHE, 8058
NLS Pharmaceutics Ltd is a biopharmaceutical company. It is engaged in the discovery and development of life-improving drug therapies to treat rare and complex CNS disorders. It focuses on developing therapeutics for the treatment of neurobehavioral and neurocognitive disorders. The company's tangible assets are held in the United States. Its lead products are Quilience, to treat narcolepsy and Nolazol, to treat ADHD.